Literature DB >> 20463591

Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation.

Donald M Pham1, Ram Subramanian, Samir Parekh.   

Abstract

Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) represent pulmonary complications of liver disease and portal hypertension. The underlying pathophysiology behind these entities is complex and involves different effects of vasoactive substances on the pulmonary vasculature, among them endothelin-1 and nitric oxide (NO). Hepatopulmonary syndrome results from vasodilation, intrapulmonary shunting, and hypoxia. In contrast, portopulmonary hypertension is predominantly owing to generalized vasoconstriction that leads to remodeling and an increase in pulmonary vascular resistance, but is rarely associated with hypoxia. We present a case report in which these 2 processes with opposing pathologic mechanisms coexist in the same patient. We also conducted a literature search to identify other documented cases of coexisting hepatopulmonary syndrome and portopulmonary hypertension, common clinical features of these patients, and outcomes with or without treatment. Our case highlights the importance of recognizing the coexistence of these 2 disease processes, as they may occur simultaneously and affect the approach to treatment, including liver transplantation.

Entities:  

Mesh:

Year:  2010        PMID: 20463591     DOI: 10.1097/MCG.0b013e3181da76fc

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

Review 1.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

2.  Onset ages of hepatopulmonary syndrome and pulmonary hypertension in patients with biliary atresia.

Authors:  Takehisa Ueno; Ryuta Saka; Yuichi Takama; Hiroaki Yamanaka; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2017-09-04       Impact factor: 1.827

3.  Aggravation of hepatopulmonary syndrome after sildenafil treatment in a patient with coexisting portopulmonary hypertension.

Authors:  Seungmin Chung; Kyungho Lee; Sung-A Chang; Duk-Kyung Kim
Journal:  Korean Circ J       Date:  2015-01-26       Impact factor: 3.243

Review 4.  Hepatopulmonary syndrome: update on pathogenesis and clinical features.

Authors:  Junlan Zhang; Michael B Fallon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

5.  A rare cause of hypoxia in a patient with liver cirrhosis.

Authors:  Amita Singh; Ankur Girdhar; Faisal Usman; James Cury; Abubakr Bajwa
Journal:  Respir Med Case Rep       Date:  2012-08-09

6.  A 45-Year-Old Undiagnosed Cirrhotic Patient with Hepatopulmonary Syndrome as First Presentation: A Case Report.

Authors:  Chetan Dhoble; Neelima Saoji; Jitesh Jeswani; Rosa Rios
Journal:  Am J Case Rep       Date:  2015-10-22

7.  Pulse oximeter oxygen saturation in prediction of arterial oxygen saturation in liver transplant candidates.

Authors:  Seiyed Mohammad Ali Ghayumi; Abolfazl Khalafi-Nezhad; Zahra Jowkar
Journal:  Hepat Mon       Date:  2014-04-07       Impact factor: 0.660

8.  Transition from hepatopulmonary syndrome to portopulmonary hypertension: a case series of 3 patients.

Authors:  Radhika Zopey; Irawan Susanto; Igor Barjaktarevic; Tisha Wang
Journal:  Case Rep Pulmonol       Date:  2013-11-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.